QX008N
/ Qyuns Therap, Joincare
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 15, 2024
Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody.
(PubMed, Int Immunopharmacol)
- "These results furnish comprehensive preclinical evidence for QX008N as an innovative anti-TSLP therapeutic agent and provide a preliminary rationale for the development of combination therapies that simultaneously target the TSLP and IL-4R signaling pathways."
Combination therapy • Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • IL13
1 to 1
Of
1
Go to page
1